The European authority HERA visits HIPRA for its productive capacity in the face of future... 27/06/2024 Healthcare Access to innovation Drug discovery Industrial biotechnology The top leadership team from HERA (Health Emergency Preparedness and Response), the European Commission's authority for... Partners - HIPRA HUMAN HEALTH S.L.U.
Juan Basterra (Mikrobiomik) | "In the last 10 years, decisive steps have been taken to und... 27/06/2024 Healthcare Drug discovery Innovative drugs Mikrobiomik is working to become the first company globally to market the first biological drug based on gut microbiota... AseBio - Mikrobiomik
Oryzon announces presentation of final data from PORTICO, vafidemstat’s global Phase IIb ... 26/06/2024 Healthcare Access to innovation Rare diseases Advanced therapies Seleccionada para presentación oral. La conferencia se celebrará en Milán del 21-23 de septiembre. Partners - Oryzon Genomics
AseBio and the Ministry of Health analyze the challenges and opportunities of Artificial I... 25/06/2024 Healthcare Access to innovation The event "Challenges and Opportunities for Spain in the Application of AI in Health Data Spaces," organized by AseBio... AseBio
AseBio and the Ministry of Health analyze the challenges and opportunities of Artificial I... 25/06/2024 The event "Challenges and Opportunities for Spain in the Application of AI in Health Data Spaces," organized by AseBio... AseBio
Overcoming Challenges in the Current Biotech Landscape 24/06/2024 Biotech entrepreneurs have experienced a demanding drug development environment in the last 24 months. To succeed... Partners
Alira Health Publishes a White Paper on the Impact of New European Union Regulations on Ad... 21/06/2024 Healthcare Access to innovation Drug discovery It provides an overview of the key changes that will impact access to innovative medicines and advanced therapies in the... Partners
ORYZON presents preliminary data from ongoing Phase Ib FRIDA trial with iadademstat plus ... 14/06/2024 Healthcare Access to innovation Drug discovery Rare diseases Data from the first two cohorts demonstrated that combination of iadademstat plus gilteritinib was safe and showed... Partners - Oryzon Genomics
Investment in R&D by biotech companies grows by 17% to 1,218 million euros 12/06/2024 In 2022, the activity of biotech companies in Spain generated more than 16.6 billion euros in revenue, representing 1.5%... AseBio
Investment in R&D by biotech companies grows by 17% to 1,218 million euros 12/06/2024 Healthcare Agrifood Industrial biotechnology Private funding raised by the sector reached an all-time high, surpassing 228 million euros after a 37% increase. AseBio
